Shares of GlaxoSmithKline PLC (NYSE:GSK) have been given an average recommendation of “Hold” by the eighteen brokerages that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $44.33.

Several analysts have recently weighed in on GSK shares. Citigroup Inc. cut shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 13th. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research report on Tuesday, July 18th. BidaskClub cut shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, TheStreet cut shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline PLC (GSK) Given Average Rating of “Hold” by Analysts” was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/22/glaxosmithkline-plc-gsk-given-average-rating-of-hold-by-analysts.html.

GlaxoSmithKline PLC (NYSE GSK) traded down 0.63% during mid-day trading on Friday, hitting $40.84. 8,971,913 shares of the company’s stock were exchanged. The stock has a market cap of $99.81 billion, a PE ratio of 39.57 and a beta of 1.03. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.53. The stock’s 50 day moving average price is $40.51 and its 200-day moving average price is $41.53.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The firm had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities analysts expect that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, October 12th. Shareholders of record on Friday, August 11th were issued a $0.491 dividend. This represents a $1.96 dividend on an annualized basis and a yield of 4.81%. The ex-dividend date was Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 198.00%.

A number of institutional investors have recently made changes to their positions in the business. Financial Advisory Service Inc. grew its holdings in GlaxoSmithKline PLC by 10.7% in the 3rd quarter. Financial Advisory Service Inc. now owns 16,980 shares of the pharmaceutical company’s stock worth $689,000 after acquiring an additional 1,639 shares during the last quarter. Fisher Asset Management LLC grew its holdings in GlaxoSmithKline PLC by 2.3% in the 3rd quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock worth $520,827,000 after acquiring an additional 293,866 shares during the last quarter. Diamond Hill Capital Management Inc. grew its holdings in GlaxoSmithKline PLC by 2.1% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 193,983 shares of the pharmaceutical company’s stock worth $7,876,000 after acquiring an additional 3,931 shares during the last quarter. Bonness Enterprises Inc. grew its holdings in GlaxoSmithKline PLC by 75.2% in the 3rd quarter. Bonness Enterprises Inc. now owns 41,700 shares of the pharmaceutical company’s stock worth $1,693,000 after acquiring an additional 17,900 shares during the last quarter. Finally, Fulton Bank N.A. grew its holdings in GlaxoSmithKline PLC by 4.9% in the 3rd quarter. Fulton Bank N.A. now owns 75,269 shares of the pharmaceutical company’s stock worth $3,056,000 after acquiring an additional 3,515 shares during the last quarter. 9.28% of the stock is currently owned by institutional investors and hedge funds.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.